In this randomized ( concealed allocation ) open-label trial , we aim to enroll up to 1,100 patients with CCC , a Rassi risk score for death prediction of 10 points , and at least 1 episode of nonsustained ventricular tachycardia on a 24-hour Holter monitoring .